With a multitude of detectable mutational markers in MDS and AML, NGS offers the opportunity and leverage for measurable residual disease (MRD) monitoring, especially in the presence of somatic driver mutations (such as NPM1, CEBPA, RUNX1, SF3B1, and others) at diagnosis. Here, SF3B1 is linked to acute myeloid leukemia.